UC Davis Health, a university hospital in Sacramento, California, has become the first customer to order the EndoDrill GI from Swedish medical device company BiBBInstruments.

The product is intended to improve cancer care with its electric-driven biopsy capabilities.

It is designed for EUS-guided tissue sampling for all indications in the gastrointestinal tract, including the pancreas, stomach, oesophagus, lymph nodes and liver.

BiBBInstruments CEO Fredrik Lindblad said: “It feels fantastic to now have our first customer in the USA, and the order is proof that we have developed an innovative biopsy product that benefits cancer care.

“This is just the beginning of our commercial journey and a small reward for the investors participating in the ongoing rights issue.”

UC Davis Health’s order comes after a successful clinical evaluation of the EndoDrill GI last year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the clinical evaluation, a scientific study detailing the outcomes of the first eight patient cases using EndoDrill GI was published.

The study highlighted a 100% diagnostic accuracy rate with only one pass, underscoring the instrument’s safety.

The EndoDrill GI is the world’s first electric-driven biopsy instrument for endoscopic ultrasound (EUS) procedures, having been cleared for use in the US with FDA 510(k) clearance in 2023 and receiving CE approval in Europe last year.

The instrument is currently being clinically evaluated in both Europe and the US, while its production is being moved to a new contract manufacturer to enable larger-scale production.

BiBBInstruments is in discussions with potential distribution partners in preparation for a wider market launch, which is expected to take place once the EndoDrill GI’s production capacity has been increased.

Based in Lund, the company develops devices to improve cancer diagnosis by taking high-quality tissue samples with high precision.

Its product portfolio is targeted towards the global market for ultrasound-guided endoscopic biopsy instruments, which is the most advanced and fast-growing area of endoscopy.